6-K ·Filed May 5, 2026
Notable filing: 6-K
Actionable Insight • Neutral
Monitor Curaleaf's next quarterly report for the financial impact of the full consolidation of Four 20 Pharma, including any purchase price allocation and revenue contribution from European operations.
Final: all horizons settled through T+60d ⚠ clustered
CURLF ▼ -16.28% at T+60d
NEUTRAL call -16.28% · α vs SPY -19.02% · entry $10.44 → $8.74
T+1d
+9.43%
call +9.43% · α +8.04%
$11.42
settled 6mo ago
T+5d
+10.92%
call +10.92% · α +8.93%
$11.58
settled 6mo ago
T+20d
-2.01%
call -2.01% · α -6.22%
$10.23
settled 5mo ago
T+60d
-16.28%
call -16.28% · α -19.02%
$8.74
settled 3mo ago
Price Chart
Loading chart...
Executive Summary
Curaleaf completed the buyout of the remaining 45% stake in German medical cannabis firm Four 20 Pharma, strengthening its vertically integrated European supply chain. No financial terms of the acquisition were disclosed in the filing.
Key Facts
- Curaleaf acquired the remaining 45% of Four 20 Pharma GmbH, a EU-GMP/GDP licensed German medical cannabis producer and distributor.
- The acquisition strengthens Curaleaf's vertically integrated global supply chain from cultivation in Portugal and Canada to distribution in Germany and other European markets.
- The company has already launched Four 20 Pharma's brand in the UK and Poland and plans further international expansion.
- No financial details (purchase price, expected synergies) were disclosed in the filing.
Financial Impact
Undisclosed; acquisition of remaining 45% stake in a private German company with 110 employees.
revenueebitda
Risk Factors
- No deal value disclosed, making it difficult to assess dilution or leverage impact.
- Regulatory risks in European medical cannabis markets remain.
- Integration risks associated with full ownership of a foreign subsidiary.
Market Snapshot
Exchange
OTC
Sector
Medicinal Chemicals & Botanical Products
Analyst Consensus
92% bullish (12 analysts)
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001756770-26-000029 |
| Document: a2026-04x30xcuraleafxcom.htm | 0001756770-26-000029 |
| Document: 0001756770-26-000029-index-headers.html | 0001756770-26-000029 |
| Document: 0001756770-26-000029-index.html | 0001756770-26-000029 |
| Document: 0001756770-26-000029.txt | 0001756770-26-000029 |
27 reports for CURLF
33% Hit rate @ T+5 Went positive at some point 3 of 9 best @ T+20▲ +25.51%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 28, 2026 today | 8-K / 425 | $8.57 | awaiting T+5 | awaiting T+5 | $8.48 (−1.05%) |
Oct 19, 2026 9d ago | 425 / 8-K | $7.86 $8.29 | ▲ +5.47% | ▲ +5.44% | $8.48 (+7.89%) |
Oct 6, 2026 22d ago | 425 | $9.99 $8.82 | ▼ −11.71% | ▼ −11.57% | $8.48 (−15.12%) |
Oct 6, 2026 22d ago | 8-K | $9.99 $8.82 | ▼ −11.71% | ▼ −11.57% | $8.48 (−15.12%) |
Oct 6, 2026 22d ago | 425 | $9.99 $8.82 | ▼ −11.71% | ▼ −11.57% | $8.48 (−15.12%) |
Oct 6, 2026 22d ago | 8-K | $9.99 $8.82 | ▼ −11.71% | ▼ −11.57% | $8.48 (−15.12%) |
Oct 1, 2026 27d ago | 8-K | $9.95 $9.39 | ▼ −5.63% | ▼ −6.79% | $8.48 (−14.77%) |
Oct 1, 2026 27d ago | 8-K | $9.95 $9.39 | ▼ −5.63% | ▼ −6.79% | $8.48 (−14.77%) |
Sep 16, 2026 6w ago | 8-K | $9.98 $11.62 | ▲ +16.43% | ▲ +13.60% | $8.48 (−15.03%) |
Sep 16, 2026 6w ago | 425 | $9.98 $11.90 | ▲ +19.24% | ▲ +17.16% | $8.48 (−15.03%) |
Showing 10 of 27
US Market Status
Market Closed · Opens Fri (12h 34m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers